Research programme: cancer vaccines - Advaxis

Drug Profile

Research programme: cancer vaccines - Advaxis

Alternative Names: Lm-LLO-CA9; Lm-LLO-cHER2-VEGFR2; ADXS-TNBC; Live attenuated Listeria-based vaccines for cancer - Advaxis/NCI; Lm-LLO-VEGF2; Lovaxin M; Lovaxin S; Lovaxin SCCE; Lovaxin W

Latest Information Update: 19 Jan 2016

Price : $50

At a glance

  • Originator University of Pennsylvania
  • Developer Advaxis; City of Hope National Medical Center
  • Class Cancer vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Leukaemia; Lymphoma

Most Recent Events

  • 08 Jan 2016 Advaxis announces intention to file IND to US FDA in 2016
  • 26 Aug 2015 Advaxis Immunotherapies and Knight Therapeutics enter into a license agreement to commercialise Advaxis's products in Canada
  • 19 May 2015 Sorrento Therapeutics and Advaxis enter into a research and clinical trial collaboration agreement for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top